Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The report covers the month of July 2025, specifically detailing a share repurchase executed on July 28, 2025. The filing serves as a regulatory disclosure of the buyback activity conducted under a non-discretionary agreement with Merrill Lynch International.
Key Financial Metrics and Transaction Details
The filing details a specific share repurchase transaction rather than providing comprehensive financial statements (revenue, profit, or cash flow are not included in this specific document).
- Shares Purchased: 490,978 ordinary shares of 31½ pence each.
- Transaction Date: July 28, 2025.
- Price Range: Lowest price paid was 1,391.00 GBp; highest price paid was 1,418.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,399.99 GBp.
- Trading Venue: London Stock Exchange (XLON). No purchases were made on CBOE Europe venues (CHIX or BATE).
- Treasury Share Holdings: Following this purchase, GSK holds 235,790,728 ordinary shares in treasury.
- Shares in Issue: 4,079,594,682 ordinary shares (excluding treasury shares).
- Treasury Voting Rights: Treasury shares represent 5.78% of the total voting rights.
Material Changes and Program Status
This transaction is part of GSK's existing buyback programme. The purchase was effected pursuant to a non-discretionary agreement entered into with Merrill Lynch International on June 4, 2025. Since the inception of this specific agreement on June 4, 2025, the Company has purchased an aggregate of 17,656,345 ordinary shares. The purchased shares are held as Treasury shares.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These factors are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and GSK's Q1 Results for 2025.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since June 4, 2025 (stated as 17,656,345).
- Confirm the current percentage of voting rights held in treasury (stated as 5.78%) against the total voting rights denominator of 4,079,594,682.
- Review the "Risk Factors" in the 2024 Form 20-F and Q1 2025 results for context on the buyback programme's strategic intent and associated risks.
- Check subsequent filings to monitor the remaining capacity or duration of the non-discretionary agreement with Merrill Lynch International.